When we evaluated the expression of CLEC12A on the CD34+CD38− compartment across IPPS‐R risk groups, we found it to be present in all of these and thus not restricted to cases with excess blasts or high‐risk MDS (Fig 1C). This evidence concerns the gene CD34 and myelodysplastic syndrome.